(Total Views: 356)
Posted On: 04/23/2019 9:52:51 PM
Post# of 72451
If we had double the number of patients in the 3wk Cisplatin B-OM arm OR if the 1wk Cisplatin B-OM arm showed the good results that the 3wk arm did, it would have been regarded a wild success and would have received BTD.
As it stands, those killer percentages are based off of 7 patients dosed PP. The other problem we're left to answer is the following:
Was the 1wk arm the anomaly and should have performed better?
OR
Was the 3wk arm the anomaly and should have performed worse?
OR
Are the signals we see in phase 2 indicative of what will happen in Phase 3?
We don't have an answer and need more patients to determine the answer. We'll get our answer in the phase 3. We'll also get pharma's thoughts based on the size of the deal.
As it stands, those killer percentages are based off of 7 patients dosed PP. The other problem we're left to answer is the following:
Was the 1wk arm the anomaly and should have performed better?
OR
Was the 3wk arm the anomaly and should have performed worse?
OR
Are the signals we see in phase 2 indicative of what will happen in Phase 3?
We don't have an answer and need more patients to determine the answer. We'll get our answer in the phase 3. We'll also get pharma's thoughts based on the size of the deal.
(0)
(0)
